Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials.

In this episode, Kelly McKee and Alicia Staley of Medidata are joined by Irfan Khan, MD, founder and CEO of Circuit Clinical, to discuss clinical trial technology adoption across patients, care teams, trial sites, and researchers and the need for industry buy-in, especially around decentralized trial technology.

Dr. Khan is a cardiologist who has served as a principal investigator on both therapeutic and device clinical trials for more than a decade. He is passionate about improving diversity in clinical trials, increasing community engagement, and fostering the patient experience through education and empowerment. Over the last six years, he has overseen Circuit Clinical’s growth to reach more than 2.5 million potential participants across 60+ active research sites.

When it comes to patient recruitment strategies, there is no one-size-fits-all approach. So how do you raise clinical trial awareness and develop innovative solutions for recruitment that break down silos and improve patient outreach?

In this episode, Kelly McKee and Alicia Staley of Medidata are joined by Tricia Barrett, Chief Operating Officer at Praxis & Crowley Webb, to discuss what an efficient direct-to-patient recruitment campaign looks like. Learn how to drive diverse patient recruitment by moving from transactional, traditional strategies to innovative, people-focused approaches.

Tricia oversees all Praxis operations from proposal generation through completed, enrolled studies. Her experience encompasses a wide range of therapeutic areas and strategies. Tricia brings a unique approach to patient recruitment that focuses on sound science and innovative execution, while always keeping the patient experience top of mind.

Is your product truly inspired by patient insights? Patient centricity is more than just a buzzword: it’s a movement. So how do you make sure your products improve the patient experience in clinical trials and alleviate patient burden?

In this episode, industry experts Kelly McKee and Alicia Staley are joined by Paul Chang, VP of Design at Medidata, to map the future of product design in clinical trials. Learn how Medidata’s patient advocates directly impact UX design to drive patient centricity across products.

Paul has spent over 20 years across a diverse range of product and design initiatives. In his role as VP of Design, he is responsible for how products and services are experienced by customers, partners, clinicians, and patients; this includes leading design strategy and building Medidata’s capabilities and reputation as a design-driven company.

As a patient, who owns your clinical trial data? Patient participation is the foundation of clinical trial research. But in today’s world, patient access to data is limited and siloed. How do researchers ensure patient data return is the standard operating procedure and information is shared with trial participants?

In this episode, Craig Lipset sits down with Kelly McKee and Alicia Staley of Medidata to discuss the challenges of data return and how to improve patient access and clinical trial data transparency.

Craig is an advisor, educator, advocate, and innovator focused on novel solutions for clinical trials and medicine development. He is the founder of Clinical Innovation Partners, Co-Chair for the Decentralized Trials & Research Alliance, and Vice Chair of the MedStar Health Research Institute. 

The U.S. population is growing increasingly diverse and ensuring that we have meaningful representation of racial and ethnic minorities and other diverse populations in clinical trials for regulated medical products is fundamental not only to FDA's regulatory mission, but also public health,” Dr. Jovonni Spinner, Associate Director of Outreach and Communications at the FDA's Office of Minority Health and Health Equity.

Related links

https://www.fda.gov/about-fda/office-commissioner/office-minority-health-and-health-equity

https://www.beaconpublichealth.com/

The simplest thing to do is to find out what kind of patients you have. Find out what cultures they are. Learn about the culture. Learn to connect. Be a human. Don't just be a robot that does science. Don't speak above someone's level. Speak to them. Put yourself in that patient's shoes, and speak to them kindly,” says Dr. Fabian Sandoval, CEO and Research Director of the Emerson Clinical Research Institute in Washington, DC, and Emmy winner and host of the weekly medical TV show "Tu Salud, Tu Familia

Currently our black and brown communities are really grossly underrepresented in cancer clinical trials, and we need to fix that. Historical barriers around egregious medical behaviors that have taken place in the past, cultural barriers, language barriers, and finally socioeconomic barriers impact the outcome of someone’s cancer journey,” says Dana Dornsife, founder and CEO at Lazarex Cancer Foundation, a nationwide non-profit org she founded in 2006.

A lot has to do with the ability to admit the painful truth about American racism in healthcare and then to make the equally painful changes that it requires,” says Harriet A. Washington, medical ethicist, American writer, and the author of Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present and Carte Blanche

Introducing Season 2 of Clinical Minds! An entire season dedicated to why diversity in clinical trials is so important and what’s being done to improve participation among underrepresented populations.

To kick things off, host Paul Oestreicher chats with Jackie Kent, evp and chief customer officer at Medidata, a Dassault Systèmes

Glen de Vries, co-founder and co CEO of Medidata and author of the upcoming book, The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19 and Beyond on how to bring together everything learned about COVID-19 to find treatments and vaccines and what can be done to make sure something like this doesn't happen again.

Dr. David Fajgenbaum, physician, scientist and author of the bestselling memoir, Chasing My Cure: A Doctor's Race to Turn Hope Into Action, on his approach to drug repurposing, how he and a team of volunteers have been applying this approach to Covid-19, and why this gives hope for all diseases with unmet need.